Caregivers’ Out-of-Pocket Expenses and Time Commitment Following Hematopoietic Stem Cell Transplantation at a Rural Cancer Center

Meehan, Kenneth R.; Meehan, John M.; Hill, John M.; Caldon, Kate L.; Root, Lynn; Labrie, Bridget M.; Brighton, Susan; Hayes, Christi Ann; Lowrey, Christopher H.

doi:10.1016/j.bbmt.2020.06.015

Cited by 9 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reduced visits to healthcare facilities with oral DEC-C treatment could also potentially lead to savings in travel costs for patients and caregivers and costs related to work absenteeism and lost wages as observed in studies conducted in other disease areas. 40 – 42 Studies evaluating HCRU and costs and persistence with oral DEC-C and IV/SC HMAs are ongoing to assess the economic benefit of oral DEC-C over parenteral HMA therapy.…”

Section: Discussionmentioning

confidence: 99%

Patients’ perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms

Zeidan,

Perepezko,

Salimi

et al. 2024

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Background: Hypomethylating agents (HMAs) are guideline-recommended treatment for higher-risk myelodysplastic syndromes/neoplasms (MDS). However, a prior survey of patients with MDS reported challenges with intravenous (IV) and subcutaneous (SC) HMA therapies, including pain related to treatment administration and interference with daily activities; most patients also indicated a preference to switch to an oral therapy if one were available. Objectives: This study evaluated the perspectives of US patients with MDS receiving oral decitabine/cedazuridine (DEC-C), an alternative to IV/SC HMAs. Methods: An online survey was conducted among adult patients with MDS in the United States (10 November 2022 to 5 December 2022) who had filled a prescription for oral DEC-C between 2021 and 2022. Results: A total of 150 patients completed the survey; 61% were aged ⩾60 years and 63% were male. Of these, 123 (82%) were still receiving oral DEC-C, and 27 (18%) had stopped oral DEC-C treatment. Half (50%) of patients had received oral DEC-C for ⩾6 months. The majority reported that treatment was convenient (83%) and that they were satisfied with treatment (86%). Most patients also reported very little/no interference with regular daily activities (82%), social activities (78%), and productivity (78%). When queried about negative impacts on quality of life (QOL), treatment side effects were the most commonly reported (30% of respondents). Among patients who had previously received IV/SC HMAs ( n = 91), most agreed that oral DEC-C interfered less with daily life (91%) and had experienced improvement in QOL (85%) compared with previous treatment; 91% reported that oral DEC-C reduced the number of times they needed to travel to a healthcare facility. Conclusion: Survey results suggest very little/no impact on regular daily activities and improved QOL with oral DEC-C relative to IV/SC HMAs, highlighting the potential for oral DEC-C to reduce the treatment burden associated with parenteral HMA therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Patients’ perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms

Zeidan,

Perepezko,

Salimi

et al. 2024

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

show abstract

“…34 As suggested in prior research, findings from the current study also indicate that caregivers may be more affected by the dayto-day financial implications of the patient's treatment and other caregiver-related out-of-pocket expenses for accommodations, transportation, and food and lost wages from work. 11,35 Pre-/postintervention improvements in psychological response, material conditions, and total FT scores suggest that CC Links is a promising approach to addressing FT among patients and caregivers in hematologic cancer treatment settings. These findings address significant gaps in evidence on OFN: only two OFN interventions that included patients with hematologic cancer have been published.…”

Section: Discussionmentioning

confidence: 99%

“…34 As suggested in prior research, findings from the current study also indicate that caregivers may be more affected by the day-to-day financial implications of the patient's treatment and other caregiver-related out-of-pocket expenses for accommodations, transportation, and food and lost wages from work. 11 , 35 …”

Section: Discussionmentioning

confidence: 99%

Coverage and Cost-of-Care Links: Addressing Financial Toxicity Among Patients With Hematologic Cancer and Their Caregivers

Edward

McLouth

Rayens

et al. 2023

JCO Oncology Practice

View full text Add to dashboard Cite

PURPOSE: This study examined the feasibility, acceptability, and preliminary effectiveness of an oncology financial navigation (OFN) intervention, Coverage and Cost-of-Care Links ( CC Links), among patients with hematologic cancer and their caregivers who are at increased risk of experiencing financial toxicity (FT). METHODS: All patients who presented to the Division of Hematology and Bone and Marrow Transplant (BMT) at an National Cancer Institute–designated cancer center between April 2021 and January 2022 were screened for FT during inpatient and outpatient visits. Patients who screened positive for FT and met the inclusion criteria were recruited to participate in CC Links that provided financial navigation and assistance via a financial navigator. Caregivers of patients undergoing BMTs were also recruited to participate. Primary outcomes were defined as improvements in FT, distress, and physical and mental quality of life. RESULTS: Fifty-four patients and 32 caregivers completed the intervention and pre-/postintervention surveys. CC Links resulted in statistically significant decreases in the Comprehensive Score for FT for both patients (| t| = 2.42, P = .019) and caregivers (| t| = 2.43, P = .021) and total FT (| t| = 2.13, P = .041) and material conditions scores (| t| = 2.25, P = .031) for caregivers only. Only 27% of eligible patients participated in the study, whereas 100% of eligible caregivers participated. The majority of participants rated the intervention highly for acceptability (89%) and appropriateness (88%). An average of $2,500 (USD) in financial benefits was secured per participant via CC Links. CONCLUSION: CC Links was effective in decreasing FT among patients with hematologic cancer and their caregivers while demonstrating high acceptability and appropriateness ratings.

show abstract

“…Data from this patient population has reported not only worsened financial toxicity, but also decreased overall survival as distance from the transplant center increases. 17 , 18 Thus, as the average distance driven to reach a phase I center is over 300 miles, 19 future research could explore the role of telemedicine, local partnerships, and decentralization of clinical trials in reducing travel-related costs and expanding access to rural or socioeconomically disadvantaged communities.…”

Section: Discussionmentioning

confidence: 99%

The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials

Williams,

Meyer,

Kawam

et al. 2023

Mayo Clinic Proceedings: Innovations, Quality & Outcomes

View full text Add to dashboard Cite

Caregivers’ Out-of-Pocket Expenses and Time Commitment Following Hematopoietic Stem Cell Transplantation at a Rural Cancer Center

Cited by 9 publications

References 20 publications

Patients’ perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms

Patients’ perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms

Coverage and Cost-of-Care Links: Addressing Financial Toxicity Among Patients With Hematologic Cancer and Their Caregivers

The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials

Contact Info

Product

Resources

About